BioCryst Pharmaceuticals, Inc. (BCRX)
NEUTRALFondamentale
63
Prezzo
$9.81
Capitalizzazione
$2.43B
Parte 1 · Quanto vale l'azienda
Panoramica
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Per questa società non c'è ancora una scheda redazionale
Per questa società non c'è ancora un elenco di concorrenti.
Stato Patrimoniale e Liquidità
Ricavi
$941M
Ultimi 12 mesi (al 30/06/2026)
Utile Netto
$-385M
Ultimi 12 mesi (al 30/06/2026)
Free Cash Flow
$345M
Patrimonio Netto Totale
$-119M
Passività Totali
$633M
Rapporto di Liquidità
2.32
Copertura Interessi
4.16
Debito/EBITDA
1.20
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$26.93
Prezzo Attuale
$9.81
Margine di Sicurezza
+63.6%
Range Fair Value
$20.10 - $33.76
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
7.86
ROE
-221.4%
Rapporto P/B
-
P/FCF
6.62
Margine Lordo
97.8%
ROIC
-70.9%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
-70.9%
WACC
9.0%
ROIC − WACC
-79.9 pp
Il ROIC è sotto il costo del capitale: l'azienda distrugge valore per ogni dollaro investito.
Criteri di Analisi Fondamentale
Superati (13)
- EPS shows upward trend
- Gross Margin 97.8%
- P/FCF 6.62
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Low reliance on intangibles
- DCF valuation (Undervalued)
- Revenue Growth 5Y 117.9%
- Analyst Consensus 88% Buy
- Piotroski F-Score 7/9
Non superati (8)
- Price CAGR 4.20%
- ROIC -70.9%
- Operating Margin -33.3%
- Return on Tangible Assets
- ROE -328.8%
- Earnings Surprise avg -35.2%
- Share Dilution 5.5%
- Net Margin Trend -40.9% vs -6.4%
Non disponibili (6)
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Salute finanziaria forte
Qualità degli Utili
Bassa qualità: indagare la contabilità
Diluizione Azionaria
Emissione nuove azioni, diluizione proprietà
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Mr. Charles K. Gayer | CEO, President & Director | 54 |
| Mr. Babar Ghias | CFO & Head of Corporate Development | 46 |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 59 |
| Mr. John Ruesch | Chief Technical Operations Officer | - |
| Dr. David W. Jenkins M.A., Ph.D. | Chief Scientific Officer | - |
| Nick Wilder | Manager of Investor Relations | - |
| Ms. Stephanie Angelini | Chief People Officer & Chief Communications Officer | - |
| Dr. William P. Sheridan MBBS | Chief Development Officer | 70 |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer | 72 |
| Ms. Jinky Ang Rosselli | Chief Data Innovation Officer | - |
Rischio Audit
8
Rischio CdA
3
Rischio Compensi
10
Rischio Diritti Azionisti
8
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Ultime Notizie
Ultime notizie per BCRX, da Markets Gazette.
- 5/6/2026NEUTRALFull Transcript: BioCryst Pharma Q1 2026 Earnings Call
BioCryst Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. The transcript, which is available for review, details the company's financial performance and strategic outlook for the first quarter of 2026. Investors and analysts can access the full transcript to gain insights into the company's operational updates, pipeline progress, and future guidance. As this is an informational event, no immediate market reaction is implied without further specific financial data or forward-looking statements being disclosed within this summary.
via Markets Gazette